View More View Less
  • 1 XV. ker. Onkológiai Szakrendelés / Gondozó 1064 Budapest Vörösmarty utca 31.
Restricted access

Valószínűleg az antraciklinek tekintendők az emlőrák – valamint az egyéb szolid tumorok és az egyes malignus hematológiai kórképek – legaktívabb gyógyszereinek. Sajnos, a dózistól függő kardiotoxicitásuk van, mely progresszív szívizom-károsodáshoz vezethet, és korlátozza a beadható maximális kumulatív dózist. Az áttekintő közlemény a nem pegilált liposzomális doxorubicinre (Myocet®) koncentrál, melyet a szabad doxorubicin terápiás indexének javítása céljából alakítottak ki. A doxorubicinnek egy makromolekuláris vektorba (liposzómába) való foglalása révén egy nanorészecske alapú gyógyszerhordozó rendszer jön létre, melynek következtében csökken a gyógyszer megoszlási volumene, csökken az ép szövetekre gyakorolt toxicitás, ugyanakkor növekszik a daganatban elérhető koncentráció. A leggyakoribb mellékhatás a neutropenia, mely a szabad doxorubicinnel szerzett előzetes tapasztalatoknak felel meg. A rendelkezésre álló bizonyítékok szerint a hematológiai toxicitás is enyhébb a konvencionális doxorubicin mellett észlelteknél. A Myocet® monoterápiában, vagy kombinációkban hatásos és biztonságos gyógyszer, ritkább és enyhébb kardiális mellékhatásokkal jár. Magyar Onkológia 54: 359–367, 2010

  • 1.

    Alvarez I Modolell A Mayordomo JI , et al. Biweekly nonpegylated liposomal doxorubicin (M) and docetaxel (T) as neoadjuvant treatment in patients with stage II-III breast cancer. J Clin Oncol 25 (18S): 11049, 2007.

    • Search Google Scholar
    • Export Citation
  • 2.

    Amadori D Gasparini G Vannozzi MO , et al. First line treatment of HER-2/neu positive advanced breast cancer patients with liposomal doxorubicin (Myocet), docetaxel and trastuzumab. A phase I-II study. J Clin Oncol 24 (18S): 10744, 2006.

    • Search Google Scholar
    • Export Citation
  • 3.

    Angioli R Palaia I Calcagno M , et al. Liposome-encapsulated doxorubicin citrate in previously treated recurrent/metastatic gynecological malignancies. Int J Gynecol Cancer 17: 8893, 2007.

    • Search Google Scholar
    • Export Citation
  • 4.

    Antolin S Mata JG Ramos M , et al. Docetaxel (D) and gemcitabine (G) followed by liposomal doxorubicin (LD) as first-line sequential therapy in metastatic breast cancer: safety results in ongoing galician study. Ann Oncol 17 (Suppl 9): ix84, Abstr. 200, 2006.

    • Search Google Scholar
    • Export Citation
  • 5.

    Antón A Ruiz A Segui MA , et al. Phase I clinical trial of liposomal-encapsulated doxorubicin citrate and docetaxel, associated with trastuzumab, as neo-adjuvant treatment in stages II and IIIA, HER2-overexpressing breast cancer patients. GEICAM 2003-03 study. Ann Oncol 20: 454459, 2009.

    • Search Google Scholar
    • Export Citation
  • 6.

    Barrett-Lee PJ Dixon JM Farrell C , et al. Expert opinion on the use of anthracyclines in patients with advanced breast cancer at cardiac risk. Ann Oncol 20: 816827, 2009.

    • Search Google Scholar
    • Export Citation
  • 7.

    Batist G Harris L Azarnia N , et al. Improved anti-tumor response rate with decreased cardiotoxicity on non-pegylated liposomal doxorubicin compared with conventional doxorubicin in first-line treatment of metastatic breast cancer in patients who had received prior adjuvant doxorubicin: results of a retrospective analysis. Anticancer Drugs 17: 587594, 2006.

    • Search Google Scholar
    • Export Citation
  • 8.

    Batist G Ramakrishnan G Rao CS , et al. Reduced cardiotoxicity and preserved antitumor efficacy of liposome-encapsulated doxorubicin and cyclophosphamide compared with conventional doxorubicin and cyclophosphamide in a randomized, multicenter trial of metastatic breast cancer. J Clin Oncol 19: 14441454, 2001.

    • Search Google Scholar
    • Export Citation
  • 9.

    Cals L Facchini T Dohollou N , et al. Efficacy and safety of non-pegylated liposomal doxorubicin MYOCET® and docetaxel as front-line treatment in HER2-neu negative metastatic breast cancer patients: results of a phase II trial. Ann Oncol 19 (Suppl 8): viii67,148P, 2008.

    • Search Google Scholar
    • Export Citation
  • 10.

    Cals L Nouyrigat P Tchiknavorian X , et al. Non-pegylated liposomal doxorubicin and docetaxel as front-line treatment in HER2-neu negative metastatic breast cancer: safety and efficacy results. J Clin Oncol 24 (18S): 10659, 2006.

    • Search Google Scholar
    • Export Citation
  • 11.

    Cardinale D Sandri MT Marzinoni A , et al. Left ventricular dysfunction by early troponin I release after high-dose chemotherapy. J Am Coll Cardiol 36: 517522, 2000.

    • Search Google Scholar
    • Export Citation
  • 12.

    Chan S Davidson N Juozaityte E , et al. Phase III trial of liposomal doxorubicin and cyclophosphamide compared with epirubicin and cyclophosphamide as first-line therapy for metastatic breast cancer. Ann Oncol 15: 15271534, 2004.

    • Search Google Scholar
    • Export Citation
  • 13.

    Christodoulou C Costopoulos I Kalofonos HP , et al. Trastuzumab combined with pegylated liposomal doxorubicin in patients with metastatic breast cancer. Phase II study of the Hellenic Cooperative Oncology Group (HeCOG) with biomarker evaluation. Oncology 76: 275285, 2009.

    • Search Google Scholar
    • Export Citation
  • 14.

    Ciolli S Leoni F Casini C , et al. The addition of liposomal doxorubicin to bortezomib, thalidomide and dexamethasone significantly improves clinical outcome of advanced multiple myeloma. Br J Haematol 141: 814819, 2008.

    • Search Google Scholar
    • Export Citation
  • 15.

    Coltelli L Allegrini G Barletta MT , et al. Docetaxel in combination with non-pegylated liposome-encapsulated doxorubicin (Myocet®) for the treatemnt of metastatic breast cancer (MBC) patients: a phase II clinical study. Ann Oncol 19 (Suppl 9): ix96, Abstr. L40, 2008.

    • Search Google Scholar
    • Export Citation
  • 16.

    Cortes J DiCosimo S Climent MA , et al. Nonpegylated liposomal doxorubicin (TLC-D99), paclitaxel, and trastuzumab in HER-2-overexpressing breast cancer: A multicenter phase I/II study. Clin Cancer Res 15: 307314, 2009.

    • Search Google Scholar
    • Export Citation
  • 17.

    Del Barco S Colomer R Calvo L , et al. Non-pegylated liposomal doxorubicin combined with gemcitabine as first-line treatment for metastatic or locally advanced breast cancer. Final results of a phase I/II trial. Breast Cancer Res Treat 116: 351358, 2009.

    • Search Google Scholar
    • Export Citation
  • 18.

    Ewer MS Lippman SM . Type II chemotherapy-related cardiac dysfunction: time to recognize a new entity. J Clin Oncol 23: 29002902, 2005.

    • Search Google Scholar
    • Export Citation
  • 19.

    Frier M Yong SH Perkins AC , et al. Biodistribution of radiolabelled liposomal doxorubicin in mice by scintigraphic imaging. Eur J Cancer 1 (5): S215S216, 2003 Abstr. 715,.

    • Search Google Scholar
    • Export Citation
  • 20.

    Gianni L Dombernowsky P Sledge G , et al. Cardiac function following combination therapy with paclitaxel and doxorubicin: an analysis of 657 women with advanced breast cancer. Ann Oncol 12: 10671073, 2001.

    • Search Google Scholar
    • Export Citation
  • 21.

    Harris L Batist G Belt R , et al. Liposome-encapsulated doxorubicin compared with conventional doxorubicin in a randomized multicenter trial as first-line therapy of metastatic breast carcinoma. Cancer 94: 2536, 2002.

    • Search Google Scholar
    • Export Citation
  • 22.

    Heilmann V Eggermann H Sommer H , et al. Non-pegylated liposomal doxorubicin and docetaxel as first-line treatment in metastatic breast cancer. J Clin Oncol 23 (16S): Abstr.753, 2005.

    • Search Google Scholar
    • Export Citation
  • 23.

    Jones SE Savin MA Holmes FA , et al. Phase III trial comparing doxorubicin plus cyclophosphamide with docetaxel with cyclophosphamide as adjuvant therapy for operable breast cancer. J Clin Oncol 24: 53815387, 2006.

    • Search Google Scholar
    • Export Citation
  • 24.

    Leonard RCF Williams S Tulpule A , et al. Improving the therapeutic index of anthracyclin chemotherapy: Focus on liposomal doxorubicin (Myocet™). The Breast 18: 218224, 2009.

    • Search Google Scholar
    • Export Citation
  • 25.

    Levine AM Tulpule A Espina B , et al. Liposome-encapsulated doxorubicin in combination with standard agents (cyclophosphamide, vincristine, prednisone) in patients with newly diagnosed AIDS-related non-Hodgkin's lymphoma: results of therapy and correlates of response. J Clin Oncol 22: 26622670, 2004.

    • Search Google Scholar
    • Export Citation
  • 26.

    Livi L Meattini I De Luca Cardillo C , et al. Non pegylated liposomal doxorubicin in combination with cyclophosphamide and docetaxel as first-line therapy in metastatic breast cancer: a retrospective analysis. Tumori 95: 422426, 2009.

    • Search Google Scholar
    • Export Citation
  • 27.

    Lorusso V Petrucelli L Saracino V , et al. Clinical outcomes of locally advanced (LABC) or metastatic breast cancer (MBC) patients with triple-negative phenotype who received non pegylated liposomal doxorubicin plus vinorelbine or cyclophosphamide as first line chemotherapy. Ann Oncol 20 (Suppl 2): ii37ii44, Abstr. 95P, 2009.

    • Search Google Scholar
    • Export Citation
  • 28.

    Marty M Laurence V Cottu P , et al. A phase I dose escalation study of non-pegylated liposomal doxorubicin (M) and docetaxel (D) in patients (pts) with previously untreated advanced breast cancer. Ann Oncol 13 (Suppl 5): 55, Abstr. 196P, 2002.

    • Search Google Scholar
    • Export Citation
  • 29.

    Miller WH DeMichele A Fox K , et al. A Phase I/II dose escalating trial of liposomal doxorubicin (TLC D-99, Myocet™) in combination with paclitaxel (Taxol®, T) for patients (pts) with metastatic breast cancer (MBC). Proc ASCO 21 (2 Pt): 31b, 1937, 2002.

    • Search Google Scholar
    • Export Citation
  • 30.

    Modolell A Mayordomo JI Garcia-Bueno JM , et al. Multicenter phase II study of liposomal doxorubicin (M) and docetaxel (T) as neoadjuvant treatment in patients with stage II-III breast cancer. J Clin Oncol 24 (18S): Abstr.10662, 2006.

    • Search Google Scholar
    • Export Citation
  • 31.

    Myocet® summary of product characteristics. http://emc.medicines.org.uk.

  • 32.

    Nielsen OS Reichardt P Christensen TB , et al. Phase I European Organisation for Research and Treatment of Cancer study determining safety of pegylated liposomal doxorubicin (Caelyx®) in combination with ifosfamide in previously untreated adult patients with advanced or metastatic soft tissue sarcomas. Eur J Cancer 42: 23032309, 2006.

    • Search Google Scholar
    • Export Citation
  • 33.

    Niemann B Mross K Drevs J , et al. The pharmacokinetic profile of liposome-encapsulated doxorubicin (TLC D-99, Myocet™). Proc ASCO 20: 117a, 2001.

    • Search Google Scholar
    • Export Citation
  • 34.

    O'Brien ME Wigler N Inbar M , et al. Reduced cardiotoxicity and comparable efficacy in a phase III trial of pegylated liposomal doxorubicin HCl (CAELYX/Doxil) versus conventional doxorubicin for first-line treatment of metastatic breast cancer. Ann Oncol 15: 440449, 2004.

    • Search Google Scholar
    • Export Citation
  • 35.

    Paridaens R Biganzoli L Bruning P , et al. Paclitaxel versus doxorubicin as first-line single agent chemotherapy for metastatic breast cancer: A European Organization for Research and Treatment of Cancer randomized study with cross-over. J Clin Oncol 18: 724733, 2000.

    • Search Google Scholar
    • Export Citation
  • 36.

    Perez EA . Doxorubicin and paclitaxel in the treatment of advanced breast cancer: efficacy and cardiac considerations. Cancer Invest 19: 155164, 2001.

    • Search Google Scholar
    • Export Citation
  • 37.

    Piccart-Gebhart MJ Burzykowski T Buyse M , et al. Taxanes alone or in combination with anthracyclines as first-line therapy of patients with metastatic breast cancer. J Clin Oncol 26: 19801986, 2008.

    • Search Google Scholar
    • Export Citation
  • 38.

    Poletti P Bettini AC Caremoli ER , et al. Liposomal-encapsulated doxorubicin (Myocet; D-99) and vinorelbine in previously treated metastatic breast cancer patients: a feasibility study. Tumori 94: 686690, 2008.

    • Search Google Scholar
    • Export Citation
  • 39.

    Ranson MR Carmichael J O'Byrne K , et al. Treatment of advanced breast cancer with sterically stabilized liposomal doxorubicin: results of a multicenter phase II trial. J Clin Oncol 15: 31853191, 1997.

    • Search Google Scholar
    • Export Citation
  • 40.

    Rocca A Maltoni R Passardi A , et al. A phase IB dose-finding trial of liposomal doxorubicin in combination with capecitabine in patients with pretreated metastatic breast cancer. Cancer Chemother Pharmacol 65: 871876, 2010.

    • Search Google Scholar
    • Export Citation
  • 41.

    Schmid P Krocker J Jehn C , et al. Primary chemotherapy with gemcitabine as prolonged infusion, non-pegylated liposomal doxorubicin and docetaxel in patients with early breast cancer: final results of a phase II trial. Ann Oncol 16: 16241631, 2005.

    • Search Google Scholar
    • Export Citation
  • 42.

    Slamon DJ Leyland-Jones B Sahk S , et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 344: 783792, 2001.

    • Search Google Scholar
    • Export Citation
  • 43.

    Sparano JA Winer EP . Liposomal anthracyclines for breast cancer. Semin Oncol 28 (Suppl 12): 3240, 2001.

  • 44.

    Stavridi F Palmieri C . Efficacy and toxicity of nonpegylated liposomal doxorubicin in breast cancer. Expert Rev Anticancer Ther 8: 18591869, 2008.

    • Search Google Scholar
    • Export Citation
  • 45.

    Stickeler E Klar M Watermann D , et al. Pegylated liposomal doxorubicin and trastuzumab as 1st and 2nd line therapy in her2/neu positive metastatic breast cancer: a multicenter phase II trial. Breast Cancer Res Treat 117: 591598, 2009.

    • Search Google Scholar
    • Export Citation
  • 46.

    Stroppa E Bertuzzi A Di Comite G , et al. Phase I study of non-pegylated liposomal doxorubicin in combination with ifosfamide in adult patients with metastatic soft tissue sarcomas. Invest New Drugs, DOI: 10.1007/s10637-009-92887.

    • Search Google Scholar
    • Export Citation
  • 47.

    Swenson CE Perkins WR Roberts P , et al. Liposome technology and the development of Myocet™ (liposomal doxorubicin citrate). The Breast 10 (Suppl 2): 17, 2001.

    • Search Google Scholar
    • Export Citation
  • 48.

    Takemura G Fujiwara H . Doxorubicin-induced cardiomyopathy: from the cardiotoxic mechanisms to management. Prog Cardiovasc Dis 49: 330352, 2007.

    • Search Google Scholar
    • Export Citation
  • 49.

    Van Dalen EC Michiels EM Caron HN , et al. Different anthracycline derivates for reducing cardiotoxicity in cancer patients. Cochrane Database Syst Rev 2010; 5:CD005006.

    • Search Google Scholar
    • Export Citation
  • 50.

    Venturini M Bighin C Puglisi F , et al. A multicentre Phase II study of non-pegylated liposomal doxorubicin in combination with trastuzumab and docetaxel as first-line therapy in metastatic breast cancer. The Breas, 2010, DOI: 10.1016/j.breast.2010.01.018.

    • Search Google Scholar
    • Export Citation
  • 51.

    Verma S Dent S Chow BJ , et al. Metastatic breast cancer: the role of pegylated liposomal doxorubicin after conventional anthracyclines. Cancer Treat Rev 34: 391406, 2008.

    • Search Google Scholar
    • Export Citation
  • 52.

    Visani G Ferrara F Alesiani F , et al. R-COMP 21 for frail elderly patients with agressive B-cell non-Hodgkin lymphoma: a pilot study. Leuk Lympoma 49: 10811086, 2008.

    • Search Google Scholar
    • Export Citation
  • 53.

    Zuppinger C Timolati F Suter TM . Pathophysiology and diagnosis of cancer drug induced cardiomyopathy. Cardiovasc Toxicol 7: 6166, 2007.

    • Search Google Scholar
    • Export Citation

Magyar Onkológia
Language Hungarian
Size  
Year of
Foundation
1956
Publication
Programme
 
Volumes
per Year
 
Issues
per Year
 
Founder Magyar Onkológusok Társasága
Founder's
Address
H-1122 Budapest, Hungary Ráth György u. 7-9.
Publisher Akadémiai Kiadó
Publisher's
Address
H-1117 Budapest, Hungary 1516 Budapest, PO Box 245.
Responsible
Publisher
Chief Executive Officer, Akadémiai Kiadó
ISSN 0025-0244 (Print)
ISSN 2060-0399 (Online)

Monthly Content Usage

Abstract Views Full Text Views PDF Downloads
May 2021 2 0 0
Jun 2021 6 0 0
Jul 2021 3 0 0
Aug 2021 16 0 0
Sep 2021 5 0 0
Oct 2021 9 0 0
Nov 2021 0 0 0